Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Matinas BioPharma (NYSE American: MTNB) reports Q2 2024 financial results and provides a business update. Key highlights include:

1. Signed non-binding term sheet for global licensing rights to develop and commercialize oral MAT2203 for invasive aspergillosis and other fungal infections.

2. 31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program, with 6 more under evaluation.

3. Q2 2024 net loss of $5.7 million ($0.02 per share), compared to $6.1 million ($0.03 per share) in Q2 2023.

4. Cash, cash equivalents, and marketable securities of $14.3 million as of June 30, 2024.

5. Ongoing LNC platform studies in inflammation and oncology, with varying results in recent trials.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results after market close on Wednesday, August 14, 2024. The company, which focuses on developing therapies using its lipid nanocrystal (LNC) platform delivery technology, will host an investment community conference call and webcast at 4:30 p.m. Eastern time on the same day to discuss the financial results and provide a business update. Interested parties can participate in the call by dialing (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available on the IR Calendar page of the Matinas website and will be archived for six months.

Matinas BioPharma has successfully treated a 22-year-old male with a severe fungal infection using its oral drug MAT2203. The patient, initially treated with intravenous amphotericin B, showed severe renal toxicity. The switch to MAT2203 not only treated the infection but also restored renal function, allowing the patient to be discharged after six weeks.

The Compassionate/Expanded Use Access Program has treated 24 patients, with positive outcomes in reversing renal toxicity. Four additional cases are awaiting FDA approval. Matinas plans to further validate MAT2203's efficacy through its ORALTO Phase 3 trial, aiming for a New Drug Application. MAT2203 is still unapproved globally.

Matinas BioPharma will feature its oral antifungal drug MAT2203 in a fireside chat hosted by A.G.P. on June 18, 2024. The discussion will include insights from antifungal expert Dr. David S. Perlin on the antifungal landscape, the benefits of MAT2203 compared to IV-amphotericin B, and MAT2203's market potential. This oral formulation aims to treat invasive aspergillosis in patients with options. Insights into the ORALTO pivotal trial will also be shared. Participants can register to attend and ask questions during the event.

Matinas BioPharma (NYSE American: MTNB) announced promising in vitro data on their lipid nanocrystal (LNC) platform for delivering small oligonucleotides. Presented at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, the data demonstrated up to 70% gene knockdown in targeted cytokines using murine macrophages. The LNCs encapsulate and protect small oligonucleotides like ASOs and siRNA, showing successful delivery and biological activity even after exposure to gastric fluid. This could make LNCs a promising oral drug delivery platform for various therapeutic applications.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reported financial results for Q1 2024, with $10 million financing to fund development programs. Discussions continue to partner for Phase 3 trial of oral MAT2203, showing promising results in fungal infections. LNC platform expansion into inflammation and oncology is supported by positive data. Cash position is strong, with $8.1 million as of March 31, 2024, sufficient to fund operations into Q2 2025.

Matinas BioPharma Holdings, Inc. announces that Chief Medical Officer, James J. Ferguson, will present two abstracts at the ASGCT Annual Meeting on the use of its lipid nanocrystal (LNC) platform for small oligonucleotide delivery. The presentations will focus on the uptake and targeted delivery of small oligonucleotides in innate immune cells and the successful in vivo oral delivery of therapeutic anti-inflammatory mRNA-targeted oligonucleotides using the LNC platform.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report first quarter 2024 financial results on May 9, 2024. The company, known for its lipid nanocrystal platform technology, will discuss financials and business updates in a webcast. Investors can participate in the conference call or webcast to gain insights into the company's performance.

Matinas BioPharma's oral formulation MAT2203, a less invasive treatment for mucormycosis, shows efficacy in treating fungal infections in mice. The study demonstrates prolonged survival, reduced fungal burden, and improved lung infection.

The promising results suggest that MAT2203 could be a safer alternative to current treatments, with potential benefits in treating various invasive fungal infections.